Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 10, 2026 08:45 ET | Source: Propanc Biopharma, Inc.

Propanc Biopharma Executes Service Agreement with FyoniBio to Establish & Validate Pharmacokinetics Assay for Phase 1b First-In-Human Study

The purpose of the study will be used as an important tool to measure the concentration of PRP and its analytes over time upon administration to patients
March 03, 2026 08:45 ET | Source: Propanc Biopharma, Inc.

Propanc Biopharma’s Lead Asset PRP Shows >85% Tumor Growth Inhibition in Preclinical Pancreatic Models

Preclinical data shines: >85% tumor growth inhibition in pancreatic models, reduced fibrosis and resistance markers, and a gentler safety profile
February 25, 2026 05:56 ET | Source: ICPO Foundation

ICPO Foundation and the World Federation of Nuclear Medicine and Biology (WFNMB) cooperate to advance Theranostics worldwide

ICPO Foundation and the World Federation of Nuclear Medicine and Biology (WFNMB) cooperate to advance Theranostics worldwide
February 24, 2026 08:00 ET | Source: Quantum Surgical

Quantum Surgical Announces Acquisition of NeuWave Medical, Inc.

Miami, Florida, and Montpellier, France, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Quantum Surgical, a company specializing in minimally invasive robotic-assisted cancer treatment, today announced the...
January 27, 2026 08:45 ET | Source: Propanc Biopharma, Inc.

Propanc Biopharma Accelerates IP Momentum: Files Fourth Provisional Patent Application in Just Two Months – Strengthening Global Protection for Breakthrough Proenzyme Formulations

Filing four provisional patent applications...underscores our relentless drive to protect and expand our groundbreaking proenzyme technology
January 20, 2026 10:00 ET | Source: Peptinovo Biopharma Inc.

First-of-its-kind Trojan Horse Cancer Treatment Approved for Clinical Trials

ANN ARBOR, Mich., Jan. 20, 2026 (GLOBE NEWSWIRE) -- Peptinovo Biopharma, an Ann Arbor–based biotechnology company pioneering targeted cancer therapies through its first-of-its-kind proprietary PALM™...
January 20, 2026 08:45 ET | Source: Propanc Biopharma, Inc.

Propanc Biopharma Files New Provisional Patent Application for Methods of Producing Trypsinogen & Chymotrypsinogen with IP Australia

The patent application describes an optimized expression system to produce a world-first fully synthetic recombinant version of PRP
January 14, 2026 12:01 ET | Source: BCC Research LLC

BCC Research Forecasts 7.5% CAGR for Global Biological Cancer Therapies Market

Growing demand for precision medicine and next-generation cancer therapies continues to fuel the global biological therapies market.
January 07, 2026 08:05 ET | Source: ARTIS Ventures

Luminate Raises $21 Million in Funding to Expand Home Cancer Treatment

GALWAY, IRELAND, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Luminate, a healthcare technology company which helps patients to receive cancer treatments at home, has raised $21 million in an expanded Series A...
December 22, 2025 07:00 ET | Source: Propanc Biopharma, Inc.

Propanc Biopharma Publishes Impact of Proenzymes on Pancreatic Ductal Adenocarcinoma Fibroblasts in Peer Reviewed Journal

Our findings demonstrate that PRP exerts multifaceted effects specifically over the cancer associated fibroblasts (CAFs) population and tumor cells.